The Food and Drug Administration just made abortion pills easier to get. The FDA announced on Monday that it’s easing restrictions on the drug mifepristone, which is used in combination with misoprostol to induce abortions. According to the agency, women will be able to obtain a prescription for Mifeprex without having to undergo a physical exam or watch their blood pressure or heart rate before buying it online or at a pharmacy. The change comes after several states passed laws making it difficult for women who can’t afford travel expenses—and sometimes even those who can—to get the pills they need for an abortion.
The FDA just made the abortion pill easier to get
The FDA is relaxing the rules on Mifeprex, which is a combination of mifepristone and misoprostol. Mifepristone blocks progesterone receptors in the uterus, making it impossible for an embryo to implant and grow after conception. Misoprostol causes uterine contractions that expel tissue from inside your uterus—and this can happen within 72 hours after taking mifepristone (or earlier with follow-up visits).
Now that you know what happens when you take these drugs together at once (and when they’re used separately), let’s explore how they’ve been used historically:
The U.S. Food and Drug Administration relaxed its rules on the use of mifepristone, a drug used in combination with another drug to terminate a pregnancy. The change takes effect immediately and allows women to take the medication later in their pregnancy.
The U.S. Food and Drug Administration relaxed its rules on the use of mifepristone, a drug used in combination with another drug to terminate a pregnancy. The change takes effect immediately and allows women to take the medication later in their pregnancy than before, according to The New York Times.
Mifepristone blocks progesterone from being produced by the body’s ovaries, which can then stop eggs from being released from those ovary cells; this causes bleeding during pregnancy and ends an embryo’s development inside a woman’s uterus (womb). Women who have taken it within 48 hours of fertilization will no longer have any restrictions on when they can take it again during their next cycle—which would be after 12 weeks into gestation—but only if they’re given permission by their physician first!
Under the new guidelines, women can use Mifeprex up to 10 weeks after their last menstrual period — two weeks longer than under the previous instructions.
Under the new guidelines, women can use Mifeprex up to 10 weeks after their last menstrual period — two weeks longer than under the previous instructions. The change takes effect immediately and will apply nationwide, according to a news release from Planned Parenthood Federation of America (PPFA).
Using Mifeprex in combination with another drug called misoprostol, a patient was able to terminate a pregnancy 96 percent of the time, according to clinical trials conducted in 2012.
Mifepristone (also known as RU-486) is a drug used in combination with another drug to terminate a pregnancy. It works by blocking the hormone progesterone, which is essential for continuation of pregnancy.
Mifeprex allows women to end their pregnancies within one day after taking it; this has been shown to be far less effective than earlier versions of the pill, which were taken up to 49 days after conception.
The FDA approved mifepristone in France in 1988 and it soon became available over-the-counter there and elsewhere—but its use was limited because it wasn’t widely accepted by doctors. In 2002, researchers at The University Of California San Francisco led an effort that resulted in new research on how best to administer mifepristone safely without losing effectiveness as well as other innovations such as using pills rather than injections or tablets that could be taken directly into muscle tissue without being absorbed through stomach walls (which would allow them reach higher amounts).
“The agency is committed to making sure that women have access to safe and effective medical products,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “This approval expands that important effort.”
The FDA is committed to making sure that women have access to safe and effective medical products, said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “This approval expands that important effort.”
The agency is also working on a new policy that would allow health care providers to prescribe abortion pills online directly, rather than requiring them to go through pharmacies like they do now.
In a press release, Woodcock said that “we want to emphasize that use of mifepristone for medical purposes is safe and effective when used as prescribed.” The FDA has received more than 150 reports of complications from using the drug in combination with misoprostol, including one death. The agency said that while the number of reported cases is small, they have been increasing over time.